Abeona Therapeutics (ABEO) Common Equity (2010 - 2026)

Abeona Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $144.9 million for Q1 2026.

• On a quarterly basis, Common Equity rose 250.13% year-over-year to $144.9 million in Q1 2026; TTM through Mar 2026 was $144.9 million, a 250.13% increase from a year earlier, with the FY2025 full-year figure at $159.2 million, up 261.6% from the prior year.
• Common Equity fell to $144.9 million in Q1 2026 per ABEO's latest filing, from $159.2 million in the prior quarter.
• Across five years, Common Equity topped out at $171.2 million in Q3 2025 and bottomed at -$8.9 million in Q1 2024.
• The 5-year median for Common Equity is $26.8 million (2022), against an average of $57.3 million.
• Biggest YoY gain for Common Equity was 683.75% in 2024; the steepest drop was 147.39% in 2024.
• Year by year, Common Equity stood at $26.8 million in 2022, then sank by 44.6% to $14.8 million in 2023, then jumped by 196.99% to $44.0 million in 2024, then soared by 261.6% to $159.2 million in 2025, then declined by 8.97% to $144.9 million in 2026.
• Per Business Quant, the three latest ABEO Common Equity figures stand at $144.9 million (Q1 2026), $159.2 million (Q4 2025), and $171.2 million (Q3 2025).